LAVAL, Que. — Valeant Pharmaceuticals International, Inc. (TSX:VRX) has a friendly deal to acquire Synergetics USA Inc., a supplier of precision surgical devices that Valeant says will enhance its Bauch + Lomb business. Valeant is offering US$6.50 per share in cash per Synergetics share (NASDAQ:SURG). In pre-market trading, Synergetics shares were up 51 per cent at US$6.63. They closed Tuesday at US$4.39, giving Synergetics a market value of US$110 million prior to Valeant's announcement.
Â© 2015 The Canadian Press. All rights reserved., source Canadian Press DataFile